These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9250283)

  • 61. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.
    Tsubota A; Kumada H; Arase Y; Chayama K; Saitoh S; Ikeda K; Kobayashi M; Suzuki Y; Murashima N
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1077-83. PubMed ID: 10524635
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C.
    Kagawa T; Morizane T; Saito H; Miyaguchi S; Tsunematsu S; Tada S; Guevara FM; Kumagai N; Tsuchimoto K; Watanabe T
    J Hepatol; 1993 Jan; 17(1):91-6. PubMed ID: 8445225
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of ursodeoxycholic acid on hepatic steatosis in rats.
    Okan A; Astarcioglu H; Tankurt E; Sagol O; Altekin E; Astarcioglu I; Gonen O
    Dig Dis Sci; 2002 Nov; 47(11):2389-97. PubMed ID: 12452368
    [TBL] [Abstract][Full Text] [Related]  

  • 64. An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C.
    Bosch O; Tapia L; Quiroga JA; Carreño V
    J Hepatol; 1993 Feb; 17(2):146-9. PubMed ID: 8445228
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C.
    Rostaing L; Modesto A; Baron E; Cisterne JM; Chabannier MH; Durand D
    Nephron; 1996; 74(3):512-6. PubMed ID: 8938673
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients.
    Sato S; Miyake T; Tobita H; Oshima N; Ishine J; Hanaoka T; Amano Y; Kinoshita Y
    World J Gastroenterol; 2009 Jun; 15(22):2782-6. PubMed ID: 19522030
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C.
    Kaneko R; Ogawa M; Iwata T; An Y; Nakagawa M; Kusayanagi S; Kamisago S; Umeda T; Sato Y
    Clin J Gastroenterol; 2009 Aug; 2(4):296-299. PubMed ID: 26192429
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Effect of long-term ursodeoxycholic acid treatment on serum liver enzymes and serum bile acid metabolism in chronic hepatitis].
    Nakamura K; Akiyama K; Makino I
    Nihon Shokakibyo Gakkai Zasshi; 1995 Jan; 92(1):62-71. PubMed ID: 7861628
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [A long-term histological prognosis after IFN therapy for chronic hepatitis C].
    Terada M; Ikegami F; Oota M; Ooyama T; Sezai S; Ito M; Sakurai Y; Kamisaka K; Abe T; Takasu S; Tanaka Y
    Nihon Shokakibyo Gakkai Zasshi; 1997 Mar; 94(3):163-71. PubMed ID: 9095634
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and side effects of intermittent recombinant interferon-alpha 2a in chronic aggressive hepatitis C: with or without initial daily administration.
    Itoh H; Nakata H; Yokoya Y; Nakashima S; Yamanishi T; Hara T; Kawai J; Miyamoto H; Higashi K; Nishioka S
    J Gastroenterol Hepatol; 1996 Aug; 11(8):718-23. PubMed ID: 8872767
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [The therapeutic efficacy of interferon-alfa-2a (Roferon-A) in chronic hepatitis C].
    Ivashkin VT; Gorbakov VV; Lytsar' BN; Vasil'ev AP
    Ter Arkh; 1997; 69(8):31-7. PubMed ID: 9381387
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A controlled randomised trial of t-UDCA as adjuvant to interferon for treatment of chronic hepatitis C: an interferon sparing effect of t-UDCA.
    Gracielle P; Roberta S; Ornella B; Luciana D; Alessandro R; Daniela Q; Gianpaolo L; Grazia D; Lamberto B; Anna C; Maurizio F; Alberto L
    Hepatol Res; 2002 Aug; 23(4):227. PubMed ID: 12191671
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.
    Solinas A; Cossu P; Poddighe P; Tocco A; Deplano A; Garrucciu G; Diana MS
    Liver; 1993 Oct; 13(5):253-8. PubMed ID: 8259037
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study.
    Tsutsumi M; Takada A; Takase S; Sawada M
    J Gastroenterol Hepatol; 1996 Nov; 11(11):1006-11. PubMed ID: 8985817
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis.
    Lepage G; Paradis K; Lacaille F; Sénéchal L; Ronco N; Champagne J; Lenaerts C; Roy CC; Rasquin-Weber A
    J Pediatr; 1997 Jan; 130(1):52-8. PubMed ID: 9003851
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of alpha-interferon on natural killer cell activity and lymphocyte subsets in thalassemia patients with chronic hepatitis C.
    Malaponte G; Passero E; Leonardi S; Monte V; Lauria C; Mazzarino C; Sciotto A; Russo Mancuso G; Di Gregorio F; Musumeci S
    Acta Haematol; 1997; 98(2):83-8. PubMed ID: 9286304
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of type C chronic active hepatitis with interferon-alpha 2a. Treatment duration does not influence biochemical remission but does decrease the relapse rate.
    Attili AF; Natali L; Onori L; Festuccia V; Natali GF
    J Clin Gastroenterol; 1994 Oct; 19(3):214-6. PubMed ID: 7806832
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Clinical study on long-term treatment of chronic hepatitis C with interferon].
    Shoji S; Kurata M; Makita A; Hosoi H; Sakai T; Takikawa H; Miyake K; Yamanaka M; Kato A
    Nihon Shokakibyo Gakkai Zasshi; 1991 Mar; 88(3):706-13. PubMed ID: 1904507
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment of chronic hepatitis C with recombinant interferon alpha 2b.
    Terranova R; Luca S
    J Chemother; 1992 Oct; 4(5):297-302. PubMed ID: 1479419
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection.
    Fleckenstein JF; Paredes M; Thuluvath PJ
    Liver Transpl Surg; 1998 Jul; 4(4):276-9. PubMed ID: 9649640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.